Inactive Instrument

Avista Public Acquisition Corp. II

Equities

OABIV

KYG072471025

Ligand Pharmaceuticals Incorporated and Avista Public Acquisition Corp. II Announces Executive Changes

March 23, 2022 at 04:17 pm EDT

Ligand Pharmaceuticals Incorporated announced the signing of a definitive merger agreement with Avista Public Acquisition Corp. II providing for the spin-off of OmniAb Inc. The combined company will be led by Ligand's President, Matt Foehr, and will be renamed “OmniAb Inc.” Matt Foehr will lead OmniAb as CEO and will resign from his role as Ligand's President and COO at closing. Kurt Gustafson has joined the OmniAb management team as CFO, bringing over 25 years of diverse experience in corporate finance and senior management roles in growth-oriented publicly traded biopharmaceutical companies, most recently as CFO of Spectrum Pharmaceuticals.

Mr. Gustafson previously served as CFO of Halozyme Therapeutics and held senior finance roles at Amgen.

Latest news about Avista Public Acquisition Corp. II

Avista Public Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Avista Public Acquisition Corp. II(NasdaqCM:AHPA) dropped from NASDAQ Composite Index	22-11-01	CI
OmniAb, Inc. completed the acquisition of Avista Public Acquisition Corp. II from Avista Capital Holdings, L.P., Polar Asset Management Partners Inc., Citadel Advisors LLC, HGC Investment Management Inc., Beryl Capital Management LLC and others.	22-10-31	CI
Avista Public Acquisition Corp. II Announces Board and Committee Changes	22-08-25	CI
Avista Public Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Avista Public Acquisition Corp. II Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-20	CI
Avista Public Acquisition Corp. II Reports Earnings Results for the Eleven Months Ended December 31, 2021	22-03-28	CI
Ligand Pharmaceuticals to Spin Off OmniAb Business Via Merger With Avista Public Acquisition	22-03-23	MT
Ligand Pharmaceuticals Incorporated and Avista Public Acquisition Corp. II Announces Executive Changes	22-03-23	CI
OmniAb, Inc. entered into a initial draft of a non-binding letter of intent to acquire Avista Public Acquisition Corp. II for $850 million.	22-03-22	CI
Avista Public Acquisition Corp. II announced that it has received $0.75 million in funding from Avista Acquisition LP II	22-03-13	CI
Certain Class B Ordinary Shares of Avista Public Acquisition Corp. II are subject to a Lock-Up Agreement Ending on 5-FEB-2022.	22-02-04	CI
Avista Public Acquisition Corp. II(NasdaqCM:AHPA) added to NASDAQ Composite Index	21-10-01	CI
Avista Public Acquisition Corp. II has completed an IPO in the amount of $200 million.	21-08-09	CI
Avista Public Acquisition Corp. II has filed an IPO in the amount of $200 million.	21-06-17	CI

Chart Avista Public Acquisition Corp. II

Duration

Period

Chart Avista Public Acquisition Corp. II

More charts

Company Profile

Avista Public Acquisition Corp. II (APAC) is a blank check company. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus in the healthcare industry. The Company has not commenced any operations nor generated any revenues.

Sector

More about the company